Drug intelligence / Profile preview

23-valent pneumococcal polysaccharide vaccine (Jiangsu Provincial Center for Disease Control and Prevention)

Development stage
Unknown
Lead developer
Jiangsu Provincial Center for Disease Control and Prevention
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The 23-valent pneumococcal polysaccharide vaccine (23vPPV) is an inactivated vaccine composed of purified capsular polysaccharides from 23 different serotypes of Streptococcus pneumoniae. It is designed to provide active immunization against invasive pneumococcal diseases, including pneumonia, meningitis, and bacteremia, in adults and children aged two years and older. The vaccine works by stimulating the production of type-specific antibodies that enhance the opsonization and phagocytosis of the bacteria. In China, this vaccine has been available since 2006. The Jiangsu Province Centers for Disease Control and Prevention has been involved in Phase 4 clinical trials to evaluate the safety and immunogenicity of the vaccine, particularly when co-administered with other vaccines such as the trivalent inactivated influenza vaccine (TIV) in healthy children and older adults.

Other names
23-valent pneumococcal polysaccharide vaccinepneumococcal polysaccharide vaccinePneumococcal 23-polyvalent vaccinePneumococcal23-polyvalent vaccinePneumococcal-23-polyvalent vaccine
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on 23-valent pneumococcal polysaccharide vaccine (Jiangsu Provincial Center for Disease Control and Prevention).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 23-valent pneumococcal polysaccharide vaccine (Jiangsu Provincial Center for Disease Control and Prevention).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call